Intestinal Microbiota and Fecal Transplantation in Patients with Inflammatory Bowel Disease and Clostridioides difficile: An Updated Literature Review
Кишечная микробиота и трансплантация фекальной микробиоты у пациентов с воспалительными заболеваниями кишечника и инфекцией Clostridioides difficile: обновлённый обзор литературы
2025-07-25
SCID: 54.1/n5vxsahf
Discuss with AI
Clostridioides difficile infectionfecal microbiota transplantationinflammatory bowel diseaseintestinal dysbiosisulcerative colitis
Figures from the paper
Abstract (AI)
Background/Objectives: Inflammatory bowel disease (IBD) is characterized by chronic relapsing and remitting inflammation of the gastrointestinal tract. Fecal microbiota transplantation (FMT) has emerged as an FDA-approved treatment for recurrent Clostridioides difficile infections (CDIs), with promising potential in patients with IBD. This manuscript aimed to provide a comprehensive and updated review of the available literature on fecal microbiota transplantation, its clinical use in IBD in general, as well as in patients with IBD and CDI. Methods: An extensive literature search was performed from October 2024 to March 2025. All publications available within PubMed, Medline, Embase, Google Scholar, and Cochrane databases were reviewed. All original articles, case reports, review articles, systematic reviews, and meta-analyses were included. Qualitative and quantitative data were both extracted. Discussion: Intestinal microbiota is an integral part of the human body, and dysbiosis (an imbalance in the gut’s microbial community) has been linked with several pathologies. Dysbiosis in IBD is marked by reduced beneficial bacteria and increased pro-inflammatory pathogens, contributing to mucosal damage and immune dysregulation. FMT has emerged as a solution to dysbiosis, with the first case recorded in 1917. FMT has been successful in treating patients with CDI. The diagnostic value of the gut microbiome is currently being explored as a possible therapeutic approach to IBD. Several studies have assessed FMT in patients with IBD and CDI with promising results in both ulcerative colitis (UC) and Crohn’s disease (CD) but varying efficacy based on administration routes, donor selection, and processing methods. In the context of recurrent CDI in patients with IBD, FMT demonstrates a high cure rate and potential benefit in concurrently improving IBD activity. However, risks such as IBD flare-ups post-FMT remain a concern. Conclusions: FMT holds promising potential in the management of CDI in patients with IBD. By restoring microbial diversity and correcting dysbiosis, FMT offers a novel, microbiota-targeted alternative to conventional therapies. While data support its efficacy in improving disease remission, variability in outcomes underscores the need for standardized protocols and additional large-scale, controlled studies. Continued research efforts into donor selection, treatment regimens, and long-term safety will be critical to optimizing FMT’s role in IBD and CDI care as well as improving patient outcomes.
Key Findings
1
FMT has established success for treating recurrent Clostridioides difficile infection and is being investigated as a therapeutic strategy for IBD-associated dysbiosis.
2
For recurrent CDI in patients with IBD, FMT shows a high cure rate and may concurrently improve IBD activity.
3
IBD flare-ups after FMT remain a potential safety concern, despite its therapeutic promise.
4
Studies of FMT in patients with IBD and CDI report promising outcomes in both ulcerative colitis and Crohn’s disease, but efficacy varies with administration route, donor selection, and processing methods.
5
The review identifies intestinal dysbiosis in IBD as reduced beneficial bacteria and increased pro-inflammatory pathogens, contributing to mucosal damage and immune dysregulation.
Research Object
Fecal microbiota transplantation in patients with inflammatory bowel disease and Clostridioides difficile infection
Research Subject
Clinical efficacy, safety, and factors influencing FMT outcomes, including effects on IBD activity and recurrent CDI
Publication Details
Publication Date
2025-07-25
Journal
Publisher
ISSN
Cited by
9
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest